McKesson Corporation
MCK
$766.08
-0.05%
McKesson Corporation is a leading healthcare services and information technology company, primarily operating as one of the three dominant pharmaceutical wholesalers in the United States, sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies, hospitals, and healthcare providers. The company is a market leader, forming an oligopoly with Cencora and Cardinal Health that accounts for over 90% of the US pharmaceutical wholesale industry, and it has expanded its business model to include medical-surgical product distribution and a variety of pharmacy technology solutions. The current investor narrative revolves around the company's ability to navigate the low-margin, high-volume wholesale business while demonstrating consistent profitability and cash flow generation, with recent attention focused on its quarterly results showing robust revenue growth and its strategic positioning within the stable healthcare supply chain.…
MCK
McKesson Corporation
$766.08
Investment Opinion: Should I buy MCK Today?
Recommendation: Hold. The stock presents a dichotomy of strong fundamentals trapped in a weak technical and valuation setup, making immediate conviction difficult.
The company's operational performance is solid, with 11.4% YoY revenue growth, sequential margin expansion to 1.53%, and powerhouse free cash flow generation of $10.1B TTM. However, the forward P/E of 15.22x, while lower than trailing, still likely commands a premium to the sector. The unanimous bullish analyst stance is a positive, but it has not arrested the stock's 19% decline over three months, indicating the market is focused on other factors.
The thesis would upgrade to a Buy if the stock stabilizes above $800, the forward P/E compresses further towards 13x (offering a clearer margin of safety), or quarterly results demonstrate sustained margin expansion above 1.6%. It would downgrade to a Sell if revenue growth decelerates below 5%, the stock breaks decisively below the $637 support level, or free cash flow shows signs of material deterioration. Relative to its history and likely peer group, McKesson appears fairly valued to slightly overvalued, with the current price reflecting its quality but also its growth constraints.
Sign up to view all
MCK 12-Month Price Forecast
McKesson is a high-quality company in a tough spot. Its operational metrics—revenue growth, cash flow, margin trends—are all positive and support a long-term hold. However, the technical picture is severely damaged, and the valuation, while improved, may not yet be compelling enough to attract new buyers amidst the downtrend. The stance is neutral, leaning towards a potential value opportunity if the price declines further. Confidence is medium due to the clear conflict between data points. An upgrade to bullish would require a confirmed technical reversal above the downtrend line and evidence that the forward P/E discount is sustainable. A downgrade to bearish would be triggered by a breakdown below $637, invalidating the key support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on McKesson Corporation's 12-month outlook, with a consensus price target around $995.90 and implied upside of +30.0% versus the current price.
Average Target
$995.90
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$613 - $996
Analyst target range
McKesson is covered by 7 analysts, and while specific Buy/Hold/Sell ratings and a consensus target price are not provided in the dataset, the institutional ratings show a pattern of sustained bullish sentiment. Recent actions from major firms like Barclays, JP Morgan, Morgan Stanley, UBS, and TD Cowen all maintain 'Overweight', 'Buy', or 'Outperform' ratings, with no downgrades noted in the provided data, indicating a strong and stable bullish consensus among covering institutions. The absence of a specific target price range in the data limits the analysis of signal strength, but the unanimous bullish stance from key analysts, coupled with no recent downgrades, suggests high conviction in the company's fundamental outlook; however, investors should note that the provided analyst data focuses on earnings and revenue estimates, with an average EPS forecast of $78.63, implying significant growth from the recent quarterly EPS of $9.63.
Bulls vs Bears: MCK Investment Factors
The evidence presents a classic battle between strong fundamentals and weak technicals. The bull case is anchored in McKesson's robust revenue growth, exceptional cash flow, improving profitability, and dominant market position, all supported by bullish analyst sentiment. The bear case is driven by a severe price downtrend, significant underperformance, and a valuation that appears rich for a low-margin distributor. Currently, the bearish technical momentum and valuation concerns hold stronger near-term evidence, as the stock price action reflects a clear de-rating despite solid operational results. The single most important tension is whether the market will re-rate the stock higher based on its cash flow and defensive qualities, or if the premium valuation will continue to compress towards industry norms amid persistent selling pressure.
Bullish
- Strong Revenue Growth & Momentum: Revenue grew 11.4% YoY to $106.16B in Q3 FY2026, accelerating from $103.15B in Q2. This demonstrates robust demand in the core pharmaceutical distribution business and positive operational momentum.
- Exceptional Free Cash Flow Generation: The company generates massive TTM free cash flow of $10.10B. This provides significant financial flexibility for strategic investments, debt reduction, and shareholder returns, a key strength in a low-margin industry.
- Improving Profitability & Margins: Net income improved sequentially from $1.11B to $1.19B, and the operating margin expanded to 1.53% from 1.42%. This shows effective cost management and operating leverage despite thin gross margins of 3.47%.
- Dominant Market Position: McKesson is part of an oligopoly controlling over 90% of the US pharmaceutical wholesale market. This entrenched position provides a stable, recurring revenue base and significant scale advantages.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is down 19.15% over 3 months and 11.54% over 6 months, trading near 35.6% of its 52-week range. It shows severe negative momentum with a -12.46% relative strength vs. SPY over the past month.
- Premium Valuation vs. Industry Peers: The trailing P/E of 22.46x is likely at a premium to the typical mid-teens P/E for healthcare distributors. This premium is vulnerable to compression if growth expectations are not met.
- Inherently Low & Thin Profit Margins: The business model is characterized by razor-thin gross margins of 3.47% and a net margin of 1.12%. This leaves little room for error and makes profitability highly sensitive to cost pressures.
- Negative Shareholder Equity & High Debt: The debt-to-equity ratio is negative at -3.97 due to negative shareholder equity, a result of significant share buybacks. This can be a risk factor during periods of rising interest rates or financial stress.
MCK Technical Analysis
The stock is in a pronounced downtrend from its recent highs, having declined 19.15% over the past three months and 11.54% over the past six months, culminating in a current price of $766.08. This places the stock at approximately 35.6% of its 52-week range, calculated from a low of $637 to a high of $999, indicating it is much closer to its yearly low than its high, which may suggest a potential value opportunity but also reflects significant negative momentum and investor pessimism. The short-term momentum is decisively negative, with the stock down 7.62% over the past month, which accelerates the longer-term downtrend and signals persistent selling pressure; this is further evidenced by a stark negative relative strength of -12.46 versus the SPY over the same period, highlighting significant underperformance. Key technical support is clearly defined at the 52-week low of $637, while resistance lies at the recent peak and 52-week high of $999. A breakdown below the $637 support would signal a continuation of the bearish trend and potentially trigger further selling, whereas a recovery above the recent downtrend line, which began after the February peak near $995, would be necessary to suggest a reversal. The stock's beta of 0.355 indicates it is significantly less volatile than the broader market, which, while providing some downside cushion during market sell-offs, also suggests muted participation in strong market rallies.
Beta
0.35
0.35x market volatility
Max Drawdown
-27.2%
Largest decline past year
52-Week Range
$637-$999
Price range past year
Annual Return
+7.8%
Cumulative gain past year
| Period | MCK Return | S&P 500 |
|---|---|---|
| 1m | -7.6% | +4.4% |
| 3m | -19.1% | +9.3% |
| 6m | -11.5% | +10.5% |
| 1y | +7.8% | +28.8% |
| ytd | -7.0% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MCK Fundamental Analysis
McKesson's revenue trajectory remains robust, with the most recent quarterly revenue (Q3 FY2026) reaching $106.16 billion, representing a strong 11.4% year-over-year growth rate. This growth has accelerated from the prior quarter's $103.15 billion, indicating positive momentum, and is primarily driven by its massive North American Pharmaceutical Segment, which contributed $88.32 billion, alongside solid contributions from the Oncology and Prescription Technology Solutions segments. The company is consistently profitable, reporting net income of $1.19 billion for the latest quarter, translating to a net margin of 1.12%, though its gross margin remains characteristically thin for the distribution industry at 3.47%. Profitability has improved sequentially, with net income rising from $1.11 billion in Q2 and $784 million in Q1, and the operating margin expanded to 1.53% from 1.42% the previous quarter, demonstrating effective cost management in a low-margin business. The balance sheet and cash flow picture is mixed but ultimately strong, with the company generating substantial trailing twelve-month free cash flow of $10.10 billion; however, the debt-to-equity ratio is a negative -3.97 due to negative shareholder equity, a common feature in this sector due to significant share buybacks, while the current ratio of 0.85 indicates adequate but not excessive liquidity for covering short-term obligations.
Quarterly Revenue
$106.2B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.03%
Latest Quarter
Free Cash Flow
$10.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MCK Overvalued?
Given the company's positive net income of $1.19 billion, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. McKesson trades at a trailing PE of 22.46x and a forward PE of 15.22x, with the forward multiple being 32% lower, indicating the market expects significant earnings growth in the coming year. Compared to typical healthcare distribution peers, McKesson's trailing PE of 22.5x likely trades at a premium to the industry average, which often sits in the mid-teens, a premium that may be justified by its market-leading position, consistent execution, and strong cash flow generation. Historically, the stock's own PE ratio has fluctuated significantly; the current trailing PE of 22.46x is below the recent high of 29.19x seen in Q1 2026 but above the low of 11.63x from early 2021, positioning it in the middle-to-upper range of its historical band over the past few years, suggesting the market is pricing in stable, but not overly optimistic, expectations.
PE
22.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1346x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's capital structure and margin profile. The negative shareholder equity and high debt-to-equity ratio (-3.97) create balance sheet fragility, though this is partially mitigated by $10.1B in annual free cash flow. The inherently thin gross margin of 3.47% leaves profitability highly vulnerable to inflationary cost pressures or competitive pricing actions. Furthermore, revenue concentration in the low-margin North American Pharmaceutical segment ($88.32B of $106.16B) creates dependency on a single, competitive business line.
Market & Competitive Risks are highlighted by valuation compression. Trading at a trailing P/E of 22.5x, likely a premium to industry peers, the stock is susceptible to multiple contraction if growth decelerates or investor sentiment sours on defensive stocks. The low beta of 0.355, while defensive, also signals the stock may not participate fully in market recoveries. Competitive risks are moderated by the stable oligopoly structure, but regulatory changes to drug pricing or distribution models could disrupt the industry's economics.
Worst-Case Scenario involves a combination of missed earnings, a broader market sell-off, and a full valuation de-rating to its historical low P/E near 11.6x. This could trigger a breakdown below the key $637 support (the 52-week low), leading to a capitulation sell-off. From the current price of $766.08, a decline to the 52-week low represents a realistic downside of approximately -17%. A more severe scenario, incorporating a growth slowdown, could see the stock test levels 25-30% below current prices, aligning with the stock's recent max drawdown of -27.17%.
FAQ
The key risks are, in order of severity: 1) Valuation Compression: The premium P/E multiple could contract towards industry averages if growth slows. 2) Technical Breakdown: The stock is in a severe downtrend; a break below the $637 support could trigger further selling. 3) Financial Structure: Negative shareholder equity and a high debt-to-equity ratio (-3.97) create balance sheet sensitivity. 4) Operational Margin Pressure: The business runs on thin gross margins (3.47%), making profits vulnerable to cost increases. 5) Low Upside Beta: A beta of 0.355 means the stock may lag during strong market rallies.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $780 and $850 as steady execution meets tempered expectations. The Bull Case (25% probability) targets $950 to $999 if defensive cash flows are rewarded and technicals reverse. The Bear Case (15% probability) warns of a drop to $637-$730 if margins compress and valuation de-rates. The Base Case is most likely, predicated on the assumption that the company maintains its current growth and cash flow profile while the stock's technical downtrend gradually stabilizes.
MCK appears fairly valued to slightly overvalued relative to its sector. The trailing P/E of 22.5x is likely at a premium to the mid-teens average for healthcare distributors, though this may be justified by its market leadership and strong cash flow. The forward P/E of 15.2x, implying significant earnings growth, is more reasonable. Compared to its own history, with a P/E range from 11.6x to 29.2x, the current multiple is in the middle-to-upper band. The valuation implies the market expects the company to maintain its recent growth and margin trajectory, leaving little room for disappointment.
MCK is a good buy for patient, value-oriented investors who can tolerate near-term volatility, but not for short-term traders. The stock's 19% decline over three months has improved its valuation, bringing the forward P/E to 15.2x, and its $10.1B annual free cash flow provides a solid foundation. However, with the stock in a pronounced downtrend and still trading at a likely premium to industry peers, immediate upside may be limited. It becomes a more compelling buy if it approaches the $700-$730 range, offering a better margin of safety against the key downside risk of valuation compression.
MCK is far more suitable for a long-term investment horizon (3-5 years minimum) than for short-term trading. Its low beta (0.355) and defensive business model are tailored for stability and compounding over time, not rapid price appreciation. Short-term traders face significant headwinds from the persistent downtrend and negative momentum. Long-term investors can benefit from the company's durable market position, massive cash generation, and shareholder returns through buybacks, allowing time for valuation concerns to resolve and for the technical picture to repair itself.